Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Impending critical data for AstraZeneca's PD-1 inhibitor Imfinzi, which is expected to be the backbone of the company's growing cancer immunotherapy portfolio, and speculation around CEO Pascal Soriot's recent trip to Israel, where it is rumored he met with a rival pharma company about its vacant chief exec role, will be hot topics during the company's second-quarter earnings call this week.
Latest From Companies
Japan's Mitsubishi Tanabe Pharma is offering to buy Israeli CNS specialist NeuroDerm for $1.1bn and the 79% pre-rumor stock price premium may put off other potential suitors.
A mid-stage trial of a Bayer/Morphosys antibody-drug conjugate for mesothelioma has failed, crossing one indication off the list of its potential uses, but development in other indications continues.
Roche's checkpoint inhibitor Tecentriq clears the EU approval hurdle in locally advanced or metastatic urothelial carcinoma and locally advanced or metastatic non-small cell lung cancer.
While Dupixent looks set for use in Europe for treating moderate-to-severe atopic dermatitis, analysts believe the biologic has a great future in other indications and could eventually become a blockbuster.
Alembic Pharmaceuticals’ first quarter earnings were weighed down by transitional disturbances pertaining to India’s new goods and services tax (GST) regime, potentially signaling an industry-wide trend, although likely temporary.
Barcelona-based Oryzon Genomics remains upbeat about the prospects for 'a first-in-class, best-in-class LSD1 inhibitor' for cancer even though Roche has walked away from what was a potentially lucrative partnership.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.